Delivery Order SPE2DB22D9353-SPE2DB25FX2AJ
Award Date 7/31/25
Potential Completion Date 8/21/25
Potential Value $30K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $52,599.60, is for the delivery of 3,750 units of the pharmaceutical product Asparlas (5 ml vial) by September 14, 2023. DMS Pharmaceutical Group holds a large Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $27,614.78 fixed-price contract is for the delivery of 3,750 units of the drug Asparlas (5 mL vials) with a performance period through May 13, 2024. The award is issued under DMS Pharmaceutical Group's $499,999,999 single-award indefinite delivery contract (IDC) with the DLA, which allows the agency to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $29,616.86 delivery order is for the supply of 3,750 units of the 5 mL vial of the drug ASPARLAS, with a performance period ending on June 4, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $27,614.78, is for the delivery of 3,750 units of the drug ASPARLAS (5 mL vials) with a completion date of May 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
- The U.S. Defense Logistics Agency awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of 3,750 units of the pharmaceutical product ASPARLAS in 5 mL vials. The contract has a potential value of $55,229.58 and a completion date of March 13, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA valued at up to $4,999,999, which enables the agency to order a...
- This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,299.79, is for the delivery of 3,750 units of the medication Asparlas (asparagine-specific enzyme) in 5 mL vials. This order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of 3,750 units of the drug ASPARLAS (5 ML vial) with a ceiling value of $82,844.34. This delivery order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the DLA to issue delivery orders...
- This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $78,899.37 contract is for the delivery of 3,750 units of the drug Asparlas (5 ml vial) with a completion date of November 30, 2023. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide...
- This federal contract award, with the ID SPE2DB20D9127|SPE2DB24FPPR7, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $55,229.58 firm fixed-price delivery order is for the provision of 3,750 units of the 5 mL vial of the drug ASPARLAS. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
- This firm fixed-price delivery order, valued at $248,533.02, was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which has a completion date of May 6, 2024, is for the delivery of 3,750 units of the oncology drug ASPARLAS in 5 mL vials. DMS Pharmaceutical Group Inc. holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...